Outlook Therapeutics

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell OTLK and other ETFs, options, and stocks.

About OTLK

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. 

CEO
C. Russell Trenary
CEOC. Russell Trenary
Employees
9
Employees9
Headquarters
Iselin, New Jersey
HeadquartersIselin, New Jersey
Founded
2010
Founded2010
Employees
9
Employees9

OTLK Key Statistics

Market cap
246.58M
Market cap246.58M
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
284.11K
Average volume284.11K
High today
$1.10
High today$1.10
Low today
$1.01
Low today$1.01
Open price
$1.07
Open price$1.07
Volume
469.82K
Volume469.82K
52 Week high
$2.12
52 Week high$2.12
52 Week low
$0.6839
52 Week low$0.6839

OTLK News

Yahoo Finance 3d
Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference - Yahoo Finance

Outlook Therapeutics, Inc. Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics to participate in a live moderated panel discussion on T...

Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference - Yahoo Finance

OTLK Earnings

-$0.09
-$0.06
-$0.03
$0.00
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Estimated
per share
Estimated per share
Actual
Expected Dec 22, Pre-Market
ActualExpected Dec 22, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.